Sanofi(US:SNY)2023-02-23 16:00Financial Performance - FDA approved ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A, leading to a €2,154 million impairment reversal impacting 2022 IFRS net income[1][2] - Adjusted IFRS net income for 2022 is €8,371 million, a 34.5% increase from the previous figure of €6,720 million[2][4] - Earnings per share (IFRS EPS) for 2022 increased to €6.69, up 34.6% from €5.37[2][4] - IFRS net sales for Q4 2022 were €10,725 million, reflecting a 7.3% increase, and total 2022 net sales reached €42,997 million, a 13.9% increase[4] - Business operating income for 2022 was €13,040 million, a 21.7% increase year-over-year[4] - Free cash flow for 2022 amounted to €8,483 million, representing a 4.8% increase[4] - Business net income for 2022 remained unchanged at €10,341 million, with a 25.9% increase year-over-year[3][4] - The total equity for the company as of December 31, 2022, is €75,152 million, up from €73,512 million[2][4] Strategic Focus - The company continues to focus on innovative healthcare solutions and expanding its market presence globally[6] - Sanofi's commitment to sustainability and social responsibility remains central to its business strategy[6]